使用司替戊醇引起食欲下降和体重下降怎么办？

(stiripentol, Diacomit) is a cytochrome P450 inhibitor developed by Biocodex, a French company. It was first launched in the EU in 2007 and is used clinically to treat various epileptic seizures. When this product is combined with other anti-epileptic drugs such as carbamazepine, it can enhance its anti-epileptic effect and reduce the dosage of the drug. However, many patients reported that they experienced loss of appetite and weight when using stiripentol. The following is an introduction to the treatment methods.

What to do if the use of stiripentol causes loss of appetite and weight

DIACOMIT can cause appetite and weight loss. In controlled studies in patients with Dravet syndrome, decreased appetite occurred in 46% of DIACOMIT-treated patients compared with 10% of patients in the placebo group. The incidence of weight loss was 27% in the DIACOMIT-treated group and 6% in the placebo group. The incidence of nausea and vomiting was also higher in DIACOMIT-treated patients. Given the frequency of these adverse reactions, pediatric patients receiving DIACOMIT should be carefully monitored for growth. In some cases, reducing the concomitant valproate dose by 30%/week may reduce appetite and weight loss.

Management of decreased appetite and weight loss caused by stiripentol use

Decreased appetite and weight loss are serious and common side effects of stiripentol. DIACOMIT can cause frequent nausea and loss of appetite, which can lead to weight loss:

1. Your weight should be checked frequently during DIACOMIT treatment.

2. Children taking DIACOMIT should have their weight and growth checked frequently.

Recommended related articles: